A Phase I, Multi-arm, Dose Escalation Study of Brivanib Alaninate Combined With Several Chemotherapy Regimens in Subjects With Solid Tumors

Trial Profile

A Phase I, Multi-arm, Dose Escalation Study of Brivanib Alaninate Combined With Several Chemotherapy Regimens in Subjects With Solid Tumors

Completed
Phase of Trial: Phase I

Latest Information Update: 05 Jun 2015

At a glance

  • Drugs Brivanib alaninate (Primary) ; Capecitabine; Docetaxel; Doxorubicin; Ixabepilone; Paclitaxel
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 02 Jun 2015 Status changed from active, no longer recruiting to completed as ClinicalTrials.gov record.
    • 20 May 2015 Planned End Date changed from 1 Mar 2015 to 1 May 2015, according to ClinicalTrials.gov record.
    • 20 May 2015 Planned primary completion date changed from 1 Mar 2015 to 1 May 2015, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top